SCHEMBL788508

SCHEMBL788508

Cc1c(S(=O)(=O)O)sc2ccccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.47
CMA1 P23946 1/20 0.44
PRNP P04156 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
ALDH1A1 P00352 4/20 0.42
PFKFB3 Q16875 1/20 0.41
GPR3 P46089 1/20 0.41
POLB P06746 2/20 0.40
MAPT P10636 2/20 0.40
MEN1 O00255 1/20 0.40
GAA P10253 1/20 0.40
KMT2A Q03164 1/20 0.40
ALOX15 P16050 1/20 0.38
LMNA P02545 2/20 0.37
MAOB P27338 1/20 0.37
HCRTR1 O43613 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
MAPK1 P28482 1/20 0.37
TUBB4A P04350 1/20 0.36
TUBB P07437 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1575935 0.83 HSD11B1 (0.44) HSD11B1CMA1PRNPRXFP1ALDH1A1
SCHEMBL787663 0.81 HSD11B1 (0.43) HSD11B1CMA1PRNPRXFP1ALDH1A1
SCHEMBL9386310 0.79 PFKFB3 (0.48) HSD11B1CMA1PRNPRXFP1ALDH1A1
SCHEMBL7116533 0.78 MCL1 (0.51) RXFP1ALDH1A1GPR3POLBMAPT
SCHEMBL1260291 0.77 PFKFB3 (0.47) HSD11B1CMA1PRNPRXFP1ALDH1A1
SCHEMBL4658351 0.76 NPSR1 (0.47) CMA1RXFP1PFKFB3L3MBTL1MCL1
SCHEMBL2226181 0.76 NPSR1 (0.60) CMA1PFKFB3MAPTL3MBTL1
SCHEMBL3946161 0.76 PFKFB3 (0.53) CMA1PFKFB3L3MBTL1
SCHEMBL787942 0.76 CMA1 (0.51) CMA1PFKFB3L3MBTL1
Hydrochloric Acid SCHEMBL6712744 0.75 NPSR1 (0.59) CMA1PFKFB3MAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-5232723-A None JP disclosed
JP-2153576-A None JP disclosed
EP-2616450-B1 SULFONAMIDE COMPOUNDS KANCERA AB (SE) 2018-05-02 EP disclosed
EP-2616450-B1 SULFONAMIDE COMPOUNDS KANCERA AB (SE) 2018-05-02 EP disclosed
US-9233946-B2 Sulfonamide compounds KANCERA AB (SE) 2016-01-12 US disclosed
US-9233946-B2 Sulfonamide compounds KANCERA AB (SE) 2016-01-12 US disclosed
US-9233946-B2 Sulfonamide compounds KANCERA AB (SE) 2016-01-12 US disclosed
US-9198902-B2 1,4-dihydropyridine-3,5-dicarboxylate derivatives and preparation and use thereof Xuanzhu Pharma Co., Ltd. (CN) 2015-12-01 US disclosed
EP-2703398-A1 1,4-DIHYDROPYRIDINE -3,5-DICARBOXYLATE DERIVATIVES, PREPARATION METHODS AND USES THEREOF Xuanzhu Pharma Co., Ltd. (CN) 2014-03-05 EP disclosed
US-20140045896-A1 1,4-dihydropyridine-3,5-dicarboxylate Derivatives And Preparation And Use Thereof Xuanzhu Pharma Co., Ltd. (CN) 2014-02-13 US disclosed
US-7655641-B2 Sulfonamide derivatives as PPAR modulators ELI LILLY AND COMPANY (US) 2010-02-02 US disclosed
EP-2137152-A1 NOVEL BENZAMIDE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF Dong-A Pharm.Co., Ltd. (KR) 2009-12-30 EP disclosed
WO-2008114971-A1 NOVEL BENZAMIDE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF DONG-A PHARM. CO., LTD. (KR) 2008-09-25 WO disclosed
EP-1597248-B1 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS LILLY CO ELI (US) 2007-12-26 EP disclosed
US-20060217433-A1 Sulfonamide derivatives as ppar modulators ELI LILLY AND COMPANY (US) 2006-09-28 US disclosed
EP-1597248-A2 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS ELI LILLY AND COMPANY (US) 2005-11-23 EP disclosed
WO-2004073606-A2 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS ELI LILLY AND COMPANY (US) 2004-09-02 WO disclosed
JP-H05232723-A ELECTROPHOTOGRAPHIC SENSITIVE MEMBER KONICA CORP 1993-09-10 JP disclosed
JP-H02153576-A PHOTOELECTRIC CONVERSION ELEMENT RICOH CO LTD 1990-06-13 JP disclosed
US-3979180-A PHENOL, DIPHENYLAMINE, THIOPHOSPHATES, TRANSITION METAL NATIONAL DISTILLERS AND CHEMICAL CORPORATION (US) 1976-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140045896-A1 1,4-dihydropyridine-3,5-dicarboxylate Derivatives And Preparation And Use Thereof PKD1, REN, GLS HSD11B1 3333/4885CMA1 1915/4885PRNP 3927/4885
US-20060217433-A1 Sulfonamide derivatives as ppar modulators PPARD, PPARA, PPARG HSD11B1 92/4885CMA1 4529/4885PRNP 4349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.